Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.

Liu J, Wang LN.

Cochrane Database Syst Rev. 2014 Jan 8;1:CD010693. doi: 10.1002/14651858.CD010693.pub2. Review.

PMID:
24399670
[PubMed - indexed for MEDLINE]
2.

Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.

Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11.

PMID:
24029780
[PubMed - indexed for MEDLINE]
3.

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.

Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial).

Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):997-1006. doi: 10.1016/j.numecd.2012.09.003. Epub 2012 Oct 11.

PMID:
23063367
[PubMed - indexed for MEDLINE]
4.

Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.

Panicker GK, Karnad DR, Salvi V, Kothari S.

J Assoc Physicians India. 2012 Jan;60:56-61. Review.

PMID:
22715547
[PubMed - indexed for MEDLINE]
5.

Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.

Nagashima A, Watanabe R, Ogawa M, Suzuki J, Masumura M, Hishikari K, Shimizu T, Takayama K, Hirata Y, Nagai R, Isobe M.

J Cardiovasc Pharmacol. 2012 Aug;60(2):158-64. doi: 10.1097/FJC.0b013e3182592d7b.

PMID:
22561360
[PubMed - indexed for MEDLINE]
6.

Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction.

Kataoka Y, Yagi N, Kokubu N, Kasahara Y, Abe M, Otsuka Y.

Circ J. 2011;75(8):1968-74. Epub 2011 Jun 14.

PMID:
21670539
[PubMed - indexed for MEDLINE]
Free Article
7.

Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway.

Zhang HL, Xu M, Wei C, Qin AP, Liu CF, Hong LZ, Zhao XY, Liu J, Qin ZH.

Neuroscience. 2011 Mar 10;176:381-95. doi: 10.1016/j.neuroscience.2010.12.029. Epub 2010 Dec 24.

PMID:
21185913
[PubMed - indexed for MEDLINE]
8.

Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).

Erdmann E, Spanheimer R, Charbonnel B; PROactive Study Investigators.

J Diabetes. 2010 Sep;2(3):212-20. doi: 10.1111/j.1753-0407.2010.00082.x.

PMID:
20923486
[PubMed - indexed for MEDLINE]
9.

Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.

Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall M, Williams LK.

Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):437-47. doi: 10.1002/pds.1722.

PMID:
19235778
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.

Winkelmayer WC, Setoguchi S, Levin R, Solomon DH.

Arch Intern Med. 2008 Nov 24;168(21):2368-75. doi: 10.1001/archinte.168.21.2368.

PMID:
19029503
[PubMed - indexed for MEDLINE]
11.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
[PubMed - indexed for MEDLINE]
12.

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

Lincoff AM, Wolski K, Nicholls SJ, Nissen SE.

JAMA. 2007 Sep 12;298(10):1180-8.

PMID:
17848652
[PubMed - indexed for MEDLINE]
13.

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

Nissen SE, Wolski K, Topol EJ.

JAMA. 2005 Nov 23;294(20):2581-6. Epub 2005 Oct 20.

PMID:
16239637
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk